ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
BioAge Labs Inc

BioAge Labs Inc (BIOA)

5,33
0,19
(3,70%)
Fermé 22 Janvier 10:00PM
5,33
0,00
( 0,00% )
Avant marché: 10:02AM

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

Dernier
5,33
Prix Achat
4,75
Prix Vente
5,58
Volume échangé
-
0,00 Fourchette du Jour 0,00
3,85 Plage de 52 semaines 26,62
Cap du marché
Clôture Veille
5,33
Ouverture
-
Dernière Transaction
Dernière heure de transaction
-
Volume financier
-
VWAP
-
Volume moyen (3 m)
789 910
Actions en circulation
35 848 738
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-2,99
Bénéfice par action (BPA)
-1,78
Chiffre d'affairess
-
Bénéfice net
-63,85M

À propos de BioAge Labs Inc

BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights in... BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging. Azelaprag, our lead product candidate, demonstrated the ability to more than double the weight loss induced by a glucagon-like-peptide-1 receptor (GLP-1R) agonist while also restoring healthy body composition and improving muscle function in preclinical obesity models. These preclinical results are supported by our Phase 1b clinical trial in older adults on bed rest where we observed decreased muscle atrophy, preservation of muscle quality and improved metabolism in subjects treated with azelaprag over a 10-day period. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Siège social
Newark, Delaware, USA
Fondé
-
BioAge Labs Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker BIOA. Le dernier cours de clôture d'BioAge Labs était de US$5,33. Au cours de la dernière année, les actions de BioAge Labs ont été négociées dans une fourchette de prix de US$ 3,85 à US$ 26,62.

BioAge Labs compte actuellement 35 848 738 actions en circulation. La capitalisation boursière d'BioAge Labs est de US$191,07 million. BioAge Labs a un ratio cours/bénéfice (ratio PE) de -2.99.

BIOA Dernières nouvelles

The Gross Law Firm Reminds BioAge Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - BIOA

The Gross Law Firm Reminds BioAge Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - BIOA PR Newswire NEW YORK, Jan. 20, 2025 NEW YORK, Jan. 20, 2025...

BioAge Labs, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - BIOA

BioAge Labs, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - BIOA PR Newswire NEW YORK, Jan. 16, 2025 NEW YORK, Jan. 16, 2025...

BioAge Labs, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - BIOA

BioAge Labs, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - BIOA PR Newswire NEW YORK, Jan. 13, 2025 NEW YORK, Jan...

Class Action Filed Against BioAge Labs, Inc. (BIOA) - March 10, 2025 Deadline to Join - Contact The Gross Law Firm

Class Action Filed Against BioAge Labs, Inc. (BIOA) - March 10, 2025 Deadline to Join - Contact The Gross Law Firm PR Newswire NEW YORK, Jan. 9, 2025 NEW YORK, Jan. 9, 2025 /PRNewswire/ -- The...

BIOA INVESTOR ALERT: Edelson Lechtzin LLP Urges BioAge Labs, Inc. (NASDAQ: BIOA) Shareholders to Consult Legal Counsel About the Impending Lead Plaintiff Deadline in the Securities Fraud Class Action

BIOA INVESTOR ALERT: Edelson Lechtzin LLP Urges BioAge Labs, Inc. (NASDAQ: BIOA) Shareholders to Consult Legal Counsel About the Impending Lead Plaintiff Deadline in the Securities Fraud Class...

BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions

Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to identify drug targets to treat diseases related...

BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity

Decision follows observations of liver transaminitis without clinically significant symptoms in some subjects on azelaprag Company will evaluate data from patients enrolled to date and share...

BioAge Labs to Present at Goldman Sachs “Year-Ahead” Catalyst Clinic

RICHMOND, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for...

BioAge Labs to Present at Upcoming Investor Conferences

RICHMOND, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for...

BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesity Completed $238.3 million initial public offering and concurrent private placement, cash and cash...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.6313.40425531914.75.384.42931195.05930562CS
4-0.67-11.166666666766.474.44071765.34793095CS
12-19.47-78.508064516124.825.33.857899107.3280678CS
26-17.17-76.311111111122.526.623.8569771910.35626766CS
52-17.17-76.311111111122.526.623.8569771910.35626766CS
156-17.17-76.311111111122.526.623.8569771910.35626766CS
260-17.17-76.311111111122.526.623.8569771910.35626766CS

BIOA - Frequently Asked Questions (FAQ)

What is the current BioAge Labs share price?
The current share price of BioAge Labs is US$ 5,33
How many BioAge Labs shares are in issue?
BioAge Labs has 35 848 738 shares in issue
What is the market cap of BioAge Labs?
The market capitalisation of BioAge Labs is USD 191,07M
What is the 1 year trading range for BioAge Labs share price?
BioAge Labs has traded in the range of US$ 3,85 to US$ 26,62 during the past year
What is the PE ratio of BioAge Labs?
The price to earnings ratio of BioAge Labs is -2,99
What is the reporting currency for BioAge Labs?
BioAge Labs reports financial results in USD
What is the latest annual profit for BioAge Labs?
The latest annual profit of BioAge Labs is USD -63,85M
What is the registered address of BioAge Labs?
The registered address for BioAge Labs is 131 CONTINENTAL DRIVE, SUITE 301, NEW CASTLE, NEWARK, DELAWARE, 19713
What is the BioAge Labs website address?
The website address for BioAge Labs is www.bioagelabs.com
Which industry sector does BioAge Labs operate in?
BioAge Labs operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
CDIOCardio Diagnostics Holdings Inc
US$ 0,931
(53,13%)
4,46M
NEHCNew Era Helium Inc
US$ 4,06
(48,18%)
799,27k
IPAImmunoPrecise Antibodies Ltd
US$ 0,708
(43,61%)
825,34k
ASSTAsset Entities Inc
US$ 1,28
(42,22%)
3,33M
ADAGAdagene Inc
US$ 2,50
(41,08%)
1
TMCITreace Medical Concepts Inc
US$ 7,23
(-22,01%)
6
ELVNEnliven Therapeutics Inc
US$ 17,21
(-21,77%)
1
STFSStar Fashion Culture Holdings Ltd
US$ 10,90
(-19,32%)
3,03k
XENEXenon Pharmaceuticals Inc
US$ 31,51
(-19,16%)
4
LSTALisata Therapeutics Inc
US$ 3,18
(-18,46%)
22
CDIOCardio Diagnostics Holdings Inc
US$ 0,931
(53,13%)
4,46M
RIMEAlgorhythm Holdings Inc
US$ 0,0376
(8,67%)
3,39M
ASSTAsset Entities Inc
US$ 1,28
(42,22%)
3,33M
SHViShares Short Treasury Bond ETF
US$ 110,36
(0,00%)
1,8M
GCTKGlucoTrack Inc
US$ 0,1197
(-4,24%)
1,44M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées